Navigation Links
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Date:10/27/2008

cating that the early increase in flares was transient

in this treatment arm before returning to the placebo level.

The reduction of gout flares, by approximately 40%, in the every two-

week dosing arm of these randomized, controlled, clinical trials is

believed to be the first time a urate lowering therapy has demonstrated

a reduction of gout flares versus a placebo.

New results presented from the GOUT 3 study show that for patients who

have been treated with pegloticase continuously for at least 12

months, the frequency of gout flares was reduced to approximately 0.2

flares per three months in the pegloticase every two weeks group, and

0.4 flares per 3 months in the every four weeks group. This represents

a 9-fold and 4-fold reduction in the frequency of gout flares after 12

months of continuous therapy for the every two and every four weeks

groups compared to the flare frequency reported prior to study entry.

Patients and their physicians participating in GOUT 3 study view this

reduction in gout flare frequency as an important clinical benefit and

the Company believes this benefit contributes to their joint decision

to continue therapy.

-- Immunology: The Company previously reported on the immune response to

pegloticase treatment in the GOUT 1 and GOUT 2 studies, showing a high

rate of seroconversion. The presence of anti-pegloticase antibodies

was predictive of a loss of uric acid control and a greater increase in

the risk of infusion reactions, but not a greater severity of infusion

reactions, particularly in the subset of patients with the highest one-

third of antibody titer.

Results of the GOUT 3 study reported confirm that for patients treated

with pegloticase for up to 12 months showed that:

- The overwhelming m
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
2. Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health
3. UKs NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain
4. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
5. AdvanDxs PNA FISH(TM) Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
8. Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure
9. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
10. DaVita Treats Thousands of Dialysis Patients in Wake of Hurricane Ike
11. Fujitsu PalmSecure and HT Systems PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v6klp2/nanobiotechnology ... PharmaBiotech,s new report "Nanobiotechnology Applications, Markets ... An increasing use of nanobiotechnology ... anticipated. Nanotechnology will be applied at all ... for optimal delivery to diagnostic applications in ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "DNA Sequencing - ... This report briefly reviews basics of ... their applications. Current large and small sequencers are ... applications of sequencing are described including those for ...
(Date:9/2/2015)... ... September 02, 2015 , ... The wet form of ... special anti-vascular endothelial growth factor agents given by injection into the eye. Dry ... a scientific protocol for the many millions diagnosed with it. AMD usually starts ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cqsxmg/gene_therapy ) ... "Gene Therapy - Technologies, Markets and Companies" ... therapy are difficult to estimate as there is only ... in China since 2004. Gene ... estimates are based on epidemiology of diseases to be ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2
... just escaped January a notoriously depressing month because ... dank weather thats no surprise. In fact, an ... ago) was the most depressing day of the year. ... burden because of the challenges they face, their depression ...
... A biotech company moving to Madison from Chicago is ... the state. , ,Governor Jim Doyle announced earlier this ... $135,000 from the Department of Commerce Technology Venture ... (TAG) programs to help the company purchase new equipment ...
... Madison-based lab that studies learning technologies with the University of Wisconsin ... Thursday evening at the World Futurist Society meeting . The ... experience at the Academic Advanced Distributed Learning Co-Lab , Brown ... is looking to video games as a teaching tool. Read more. ...
Cached Biology Technology:Post-January, tech entrepreneurs have reasons to be depressed 2Post-January, tech entrepreneurs have reasons to be depressed 3Post-January, tech entrepreneurs have reasons to be depressed 4Tech Digest: Futurists on learning; Sonic Foundry; Accu Tech; Fiserv 2
(Date:8/24/2015)... 2015 The consulting company Frost & ... manufacturer DERMALOG and its customized solutions and products for ... of the Year Award". DERMALOG is particularly successful with a ... -Cross reference: Picture is available at AP Images ... On Thursday evening, in South Africa,s ...
(Date:8/20/2015)... CLARA, Calif. , Aug. 20, 2015 /PRNewswire/ ... company focused on improving the user experience and ... and vision technologies, today announced that its ... voice biometric authentication software to be FIDO ... tested TrulySecure for compliance with the FIDO UAF ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas ... key contributor to the Submission Content Management ... IRISS, a non-profit forum. Dedicated to the Implementation ... a neutral platform for industry, vendors, health ... information and work towards a standard method ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... show a combination of depressive symptoms and elevated levels of ... likely to develop major depression than those who show neither ... In a study published today in the Proceedings ... University of Cambridge have identified the first biomarker a ...
... non-coding RNAs can be used to predict if individuals ... Cancer Genome Atlas project. The results, which are published ... the levels of specific types of non-coding RNAs can ... These RNAs can also be used to classify cancer ...
... cancers so difficult to treat is that malignant cells from ... and blood vessels to invade new locations. Now, researchers have ... cancer by using a film of nanofibers thinner than human ... invading new areas, the migrating cells latch onto the specially-designed ...
Cached Biology News:First biological marker for major depression could enable better diagnosis and treatment 2First biological marker for major depression could enable better diagnosis and treatment 3First biological marker for major depression could enable better diagnosis and treatment 4Small non-coding RNAs could be warning signs of cancer 2Researchers hijack cancer migration mechanism to 'move' brain tumors 2Researchers hijack cancer migration mechanism to 'move' brain tumors 3Researchers hijack cancer migration mechanism to 'move' brain tumors 4
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
... utilize the membrane-permeant ester forms (CCF2-AM ... fluorescent beta-lactamase substrates, CCF2 and CCF4. ... cell, where cleavage by endogeneous cytoplasmic ... negatively charged forms, thereby trapping them ...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
... utilize the membrane-permeant ester forms (CCF2-AM ... fluorescent beta-lactamase substrates, CCF2 and CCF4. ... cell, where cleavage by endogeneous cytoplasmic ... negatively charged forms, thereby trapping them ...
Biology Products: